Taylor Sandison - 13 Mar 2023 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role
Chief Medical Officer
Signature
/s/ Shane Ward, Attorney-in-Fact
Issuer symbol
CDTX
Transactions as of
13 Mar 2023
Net transactions value
-$11,021
Form type
4
Filing time
13 Mar 2023, 21:19:53 UTC
Previous filing
13 Sep 2022
Next filing
29 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDTX Common Stock Sale $11,021 -7,203 -2.4% $1.53 288,550 13 Mar 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2 Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan ("ESPP") on November 18, 2022.